Perspective Insights into Disease Progression, Diagnostics, and Therapeutic Approaches in Alzheimer's Disease: A Judicious Update
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive accumulation of β-amyloid fibrils and abnormal tau proteins in and outside of neurons. Representing a common form of dementia, aggravation of AD with age increases the morbidity rate among the elderly. Although, mutations in the ApoE4 act as potent risk factors for sporadic AD, familial AD arises through malfunctioning of APP, PSEN-1, and-2 genes. AD progresses through accumulation of amyloid plaques (Aβ) and neurofibrillary tangles (NFTs) in brain, which interfere with neuronal communication. Cellular stress that arises through mitochondrial dysfunction, endoplasmic reticulum malfunction, and autophagy contributes significantly to the pathogenesis of AD. With high accuracy in disease diagnostics, Aβ deposition and phosphorylated tau (p-tau) are useful core biomarkers in the cerebrospinal fluid (CSF) of AD patients. Although five drugs are approved for treatment in AD, their failures in achieving complete disease cure has shifted studies toward a series of molecules capable of acting against Aβ and p-tau. Failure of biologics or compounds to cross the blood-brain barrier (BBB) in most cases advocates development of an efficient drug delivery system. Though liposomes and polymeric nanoparticles are widely adopted for drug delivery modules, their use in delivering drugs across the BBB has been overtaken by exosomes, owing to their promising results in reducing disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · cited 1×
“…a critical role in the multi-causality of dementia (Boyle et al., 2013), mutations in APP enhance aggregation, while PSEN1&2 mutations cause less efficient APP processing, leading to longer and more hydrophobic Aβs (Scheuner et al., 1996; Chávez-Gutiérrez et al., 2012; Wong et al., 2013; Table 1).”
BackgroundCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“…(FA), epigallocatechin-3-gallate, and nano formulation of naturally occurring curcumin were found exerting strong antioxidant, anti-inflammatory and amyloid disintegration properties (Rezai-Zadeh et al., 2005; Yang et al., 2005; Cheng et al., 2013; Sgarbossa et al., 2015; Cascella et al., 2017).”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“Over the time, substantial evidences regarding accumulation of misfolded Aβ and tau tangles (so-called seeds of pathological consequences) in the brain of patients suffering from AD have been established (Karran et al., 2011).”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 2×
“Though mutations in APP and PS1&2 accelerate generation of disease seeds, decreased Aβ clearance (Mawuenyega et al., 2010) and increased Aβ accumulation (Wahlster et al.”
BackgroundCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052 · cited 1×
“Though ApoE4 is a well-characterized risk factor in SAD, disease etiology in FAD is attributed to mutations of amyloid precursor protein (APP), presenilin1 (PS1), and presenilin 2 (PS2) genes (Goate et al., 1991; Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington et al., 1996; Selkoe, 2001b).”
BackgroundOxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885 · cited 1×
“Mitochondrial dysfunction, observed as alteredmitochondrial DNA and increased cytochrome oxidase (COX) levels, indicates oxidative damage to the neurons of AD patients (Hirai et al., 2001; Nunomura et al., 2001; Moreira et al., 2006, 2007, 2009; Su et al., 2008).”
BackgroundCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663 · cited 1×
“It arises as a result of progressive accumulation of β-amyloid fibrils (β-amyloid plaques) and abnormal forms of tau (tau tangles) within and outside of neurons (Jucker and Walker, 2013; Jaunmuktane et al., 2015).”
BackgroundForkhead transcription factor FOXO3a protects quiescent cells from oxidative stress
Kops, G. J. P. L., Dansen, T. B., Polderman, P. E., Saarloos, I., Wirtz, K. W. A., Coffer, P. J., Huang, T.-T., Bos, J. L., Medema, R. H., & Burgering, B. M. T. (2002) · Nature · doi:10.1038/nature01036 · Cited by 1,580 · cited 2×
“An increase in the oxidative burden of mitochondria mediates activation of FoxO transcription factor (Kops et al., 2002; Fu and Tindall, 2008), which is associated with induction of SOD and catalase activity, as well as causing cell cycle arrest and cell death (Castellani et al., 2002).”
BackgroundAutophagy, mitochondria and oxidative stress: cross-talk and redox signalling.
Lee, J., Giordano, S., & Zhang, J. (2012) · Biochemical Journal · doi:10.1042/bj20111451 · Cited by 1,438
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“Mitochondrial dysfunction, observed as alteredmitochondrial DNA and increased cytochrome oxidase (COX) levels, indicates oxidative damage to the neurons of AD patients (Hirai et al., 2001; Nunomura et al., 2001; Moreira et al., 2006, 2007, 2009; Su et al., 2008).”
BackgroundAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 2×
“Though mutations in APP and PS1&2 accelerate generation of disease seeds, decreased Aβ clearance (Mawuenyega et al., 2010) and increased Aβ accumulation (Wahlster et al., 2013) enhances”
BackgroundThe role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Ha, D., Yang, N., & Nadithe, V. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.02.001 · Cited by 1,346
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · cited 1×
“This was followed by trials of mAb m266, which showed enhanced Aβ clearance from brain to blood (Demattos et al., 2001; Dodart et al., 2002).”
MethodRegulation of autophagy by ROS: physiology and pathology
Scherz-Shouval, R., & Elazar, Z. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.07.007 · Cited by 1,263 · cited 1×
“Increased ROS levels act as an autophagy trigger and subjects mitochondria to mitophagy (Scherz-Shouval and Elazar, 2011).”
BackgroundLee, J.-H., Yu, W. H., Kumar, A., Lee, S., Mohan, P. S., Peterhoff, C. M., Wolfe, D. M., Martinez-Vicente, M., Massey, A. C., Sovak, G., et al. (2010) · Cell · doi:10.1016/j.cell.2010.05.008 · Cited by 1,212 · cited 2×
“Additionally, PS1 and PS2 serving as a catalytic subunit of γ-secretase was found acting as autophagy modulators (Lee et al., 2010).”
BackgroundThe Smart Drug Delivery System and Its Clinical Potential
Liu, D., Yang, F., Xiong, F., & Gu, N. (2016) · Theranostics · doi:10.7150/thno.14858 · Cited by 1,066
Molecular Interplay between Mammalian Target of Rapamycin (mTOR), Amyloid-β, and Tau
Caccamo, A., Majumder, S., Richardson, A., Strong, R., & Oddo, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.100420 · Cited by 881
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858
The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives
Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.010 · Cited by 786 · cited 1×
“Performing vital biochemical functions, mitochondrial dysfunction significantly affects progression in the pathogenesis of AD (Swerdlow et al., 2014).”
BackgroundIdentification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
APOE and Alzheimer disease: a major gene with semi-dominant inheritance
Genin, E., Hannequin, D., Wallon, D., Sleegers, K., Hiltunen, M., Combarros, O., Bullido, M. J., Engelborghs, S., De Deyn, P., Berr, C., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.52 · Cited by 714
Rezai-Zadeh, K., Shytle, D., Sun, N., Mori, T., Hou, H., Jeanniton, D., Ehrhart, J., Townsend, K., Zeng, J., Morgan, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1521-05.2005 · Cited by 713
Disturbance of endoplasmic reticulum proteostasis in neurodegenerative diseases
Hetz, C., & Mollereau, B. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3689 · Cited by 684 · cited 1×
“Recognition of unfolded proteins by stress sensors such as inositol requiring protein 1 (IRE1), protein kinase RNA (PKR) like ER kinase (PERK), and activating transcription factor 6 (ATF6) triggers downstream signaling via transcription factors (Hetz and Mollereau, 2014).”
BackgroundMitochondrial abnormalities in Alzheimer brain: Mechanistic implications
Bubber, P., Haroutunian, V., Fisch, G., Blass, J. P., & Gibson, G. E. (2005) · Annals of Neurology · doi:10.1002/ana.20474 · Cited by 622
Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus
Hoozemans, J. J. M., van Haastert, E. S., Nijholt, D. A. T., Rozemuller, A. J. M., Eikelenboom, P., & Scheper, W. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080814 · Cited by 600
A Phase II Trial of Tideglusib in Alzheimer's Disease
Lovestone, S., for the ARGO investigators, Boada, M., Dubois, B., Hüll, M., Rinne, J. O., Huppertz, H.-J., Calero, M., Andrés, M. V., Gómez-Carrillo, B., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141959 · Cited by 536 · cited 1×
“As Aβ promotes GSK-3β activity, studies of GSK-3β inhibitors such as tideglusib and AZD1080 were pursued (King et al., 2014; Lovestone et al., 2015).”
BackgroundEvidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Jaunmuktane, Z., Mead, S., Ellis, M., Wadsworth, J. D. F., Nicoll, A. J., Kenny, J., Launchbury, F., Linehan, J., Richard-Loendt, A., Walker, A. S., et al. (2015) · Nature · doi:10.1038/nature15369 · Cited by 518 · cited 1×
“It arises as a result of progressive accumulation of β-amyloid fibrils (β-amyloid plaques) and abnormal forms of tau (tau tangles) within and outside of neurons (Jucker and Walker, 2013; Jaunmuktane et al., 2015).”
BackgroundThe mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495 · cited 1×
“…a critical role in the multi-causality of dementia (Boyle et al., 2013), mutations in APP enhance aggregation, while PSEN1&2 mutations cause less efficient APP processing, leading to longer and more hydrophobic Aβs (Scheuner et al., 1996; Chávez-Gutiérrez et al., 2012; Wong et al., 2013; Table 1).”
BackgroundCurtis, C., Gamez, J. E., Singh, U., Sadowsky, C. H., Villena, T., Sabbagh, M. N., Beach, T. G., Duara, R., Fleisher, A. S., Frey, K. A., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4144 · Cited by 332 · cited 2×
“Despite this, assessment of the sensitivity of disease biomarkers reflects an imperfect criterion in the gold standard of clinical diagnosis of the disease because it fails to distinguish pathological changes such as plaque count between cognitively normal elderly persons and those with AD (Coart et al., 2015; Curtis…”
BackgroundMuch of late life cognitive decline is not due to common neurodegenerative pathologies
Boyle, P. A., Wilson, R. S., Yu, L., Barr, A. M., Honer, W. G., Schneider, J. A., & Bennett, D. A. (2013) · Annals of Neurology · doi:10.1002/ana.23964 · Cited by 323 · cited 2×
“Having a critical role in the multi-causality of dementia (Boyle et al., 2013), mutations in APP enhance aggregation, while PSEN1&2 mutations cause less efficient APP processing, leading to longer and more hydrophobic Aβs (Scheuner et al., 1996; Chávez-Gutiérrez et al., 2012; Wong et al., 2013;…”
BackgroundNrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52
Jo, C., Gundemir, S., Pritchard, S., Jin, Y. N., Rahman, I., & Johnson, G. V. W. (2014) · Nature Communications · doi:10.1038/ncomms4496 · Cited by 323 · cited 3×
“Studies indicate involvement of NDP-52 as a downstream facilitator of nuclear factor erythroid-2 related factor 2 (Nrf2)-mediated tau (phosphorylated) degradation (Jo et al., 2014).”
BackgroundTumbarello, D. A., Waxse, B. J., Arden, S. D., Bright, N. A., Kendrick-Jones, J., & Buss, F. (2012) · Nature Cell Biology · doi:10.1038/ncb2589 · Cited by 301 · cited 2×
“Acting as an autophagic adaptor for degradation of toll/IL-1 receptor homology domain containing adaptor including IFN-β (TRIF) and tumor receptor associated factor-6 (TRAF6), a role of NDP-52 in docking of autophagosomes to T6BP, myosin VI, and optineurin for maturation has been reported (Inomata et al., 2012; Tumbar…”
BackgroundThe ER stress factor XBP1s prevents amyloid-β neurotoxicity
Casas-Tinto, S., Zhang, Y., Sanchez-Garcia, J., Gomez-Velazquez, M., Rincon-Limas, D. E., & Fernandez-Funez, P. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr100 · Cited by 275 · cited 2×
“…against Aβ toxicity through enforced Xbp1 expression in aDrosophila melanogaster ADmodel is attributed to reduction in the release of Ca2+ from ER (Casas-Tinto et al., 2011), a similar effect in Caenorhabditis elegans AD model is correlated with augmented stress levels and enhanced autophagy…”
BackgroundWischik, C. M., Staff, R. T., Wischik, D. J., Bentham, P., Murray, A. D., Storey, J. M. D., Kook, K. A., & Harrington, C. R. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142874 · Cited by 269 · cited 1×
“LMTC, a methylthionium chloride (MTC) derivative prevents tau interactions, thereby facilitating its clearance from the brain (Wischik et al., 2015).”
BackgroundPathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242 · cited 1×
“One such biomarker involves Aβ oligomers (toxic forms of Aβ), which are associated with synaptic dysfunction (Overk and Masliah, 2014).”
BackgroundDi Domenico, F., Head, E., Butterfield, D. A., & Perluigi, M. (2014) · Advances in Geriatrics · doi:10.1155/2014/527518 · Cited by 50 · cited 1×
“Reduction in the autophagy-aggravated AD pathology underlines the critical role of autophagy in the removal of Aβ aggregates (Cai et al., 2012; Di Domenico et al., 2014).”
Background
Cited by
Plasmalogens and Alzheimer’s disease: A review
Su, X. Q., Wang, J., & Sinclair, A. J. (2019) · Lipids in Health and Disease · doi:10.1186/s12944-019-1044-1 · Cited by 172
Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases
D’Anca, M., Fenoglio, C., Serpente, M., Arosio, B., Cesari, M., Scarpini, E. A., & Galimberti, D. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00232 · Cited by 154
Extracellular vesicles as an emerging tool for the early detection of Alzheimer’s disease
Li, T.-R., Wang, X.-N., Sheng, C., Li, Y.-X., Li, F. Z.-T., Sun, Y., & Han, Y. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.111175 · Cited by 60
Metadata
- Authors
- Jan, A. T., Azam, M., Rahman, S., Almigeiti, A. M. S., Choi, D. H., Lee, E. J., Haq, Q. M. R., & Choi, I.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-11-01
- Volume
- 9
- Pages
- 356-356
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2765180668
- Cited by
- 47
- References
- 41
- FWCI
- 5.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.